

Tolerance, variability, and pharmacokinetics of bevacizumab in male subjects

Cancer Chemotherapy and Pharmacology
82, 615-623

DOI: [10.1007/s00280-018-3645-1](https://doi.org/10.1007/s00280-018-3645-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients. <i>Frontiers in Pharmacology</i> , 2018, 9, 1372.	1.6	6
2	A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers. <i>Frontiers in Pharmacology</i> , 2019, 10, 905.	1.6	9
3	A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin®) in Healthy Male Subjects. <i>BioDrugs</i> , 2019, 33, 335-342.	2.2	12
4	A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males. <i>BioDrugs</i> , 2019, 33, 173-181.	2.2	14
5	A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 567-575.	1.1	13
6	A randomized, double-blind, parallel-group, single-dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 193-202.	1.1	1
7	A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 465-474.	1.1	5
8	A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects. <i>Frontiers in Pharmacology</i> , 2021, 12, 694375.	1.6	3
9	Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study. <i>EClinicalMedicine</i> , 2021, 42, 101187.	3.2	8
11	Biosimilar monoclonal antibodies in China: A patent review. <i>Bioengineered</i> , 2022, 13, 14503-14518.	1.4	3
12	Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0